Literature DB >> 22846047

Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?

C Hermans, J Astermark, P De Moerloose.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22846047     DOI： 10.1111/j.1538-7836.2012.04871.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  2 in total

Review 1.  Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Paul Knoebl; Bernd Jilma
Journal:  Thromb Haemost       Date:  2020-07-27       Impact factor: 5.249

2.  Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.

Authors:  Brian R Long; Philippe Veron; Klaudia Kuranda; Romain Hardet; Nina Mitchell; Gregory M Hayes; Wing Yen Wong; Kelly Lau; Mingjin Li; M Benjamin Hock; Stephen J Zoog; Christian Vettermann; Federico Mingozzi; Becky Schweighardt
Journal:  Mol Ther       Date:  2020-12-10       Impact factor: 11.454
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.